The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis

Tsui PH, Huang CC, Zhou Q, Shung KK (2011) Cataract measurement by estimating the ultrasonic statistical parameter using an ultrasound needle transducer: an in vitro study. Physiol Meas 32:513–522. doi:10.1088/0967-3334/32/5/002 Isaacs R, Ram J, Apple D (2004) Cataract blindness in the developing world: is there a solution? J Agromedicine 9:207–220 Lam DS, Li EY, Chang DF, Zhang MZ, Zhan HK, Pang CP (2009) Project vision: a new and sustainable model for eliminating cataract blindness in China. Clin Exp Ophthalmol 37:427–430. doi:10.1111/j.1442-9071.2009.02084.x Shen W, Yang Y, Yu M, Li J, Wei T, Li X, Li J, Su X, Zhong H, Yuan Y (2013) Prevalence and outcomes of cataract surgery in adult rural Chinese populations of the Bai nationality in Dali: the Yunnan minority eye study. PLoS One 8:e60236. doi:10.1371/journal.pone.0060236 Rofagha S, Bhisitkul RB (2011) Management of retained lens fragments in complicated cataract surgery. Curr Opin Ophthalmol 22:137–140. doi:10.1097/ICU.0b013e3283436fc5 Jammal HM, Khader Y, Shawer R, Al Bdour M (2012) Posterior segment causes of reduced visual acuity after phacoemulsification in eyes with cataract and obscured fundus view. Clin Ophthalmol 6:1843–1848. doi:10.2147/OPTH.S38303 Melancia D, Abegão Pinto L, Marques-Neves C (2015) Cataract surgery and intraocular pressure. Ophthal Res 53:141–148. doi:10.1159/000377635 Higashide T, Sugiyama K (2008) Use of viscoelastic substance in ophthalmic surgery - focus on sodium hyaluronate. Clin Ophthalmol 2:21–30 Waterbury LD, Galindo D, Villanueva L, Nguyen C, Patel M, Borbridge L, Attar M, Schiffman RM, Hollander DA (2011) Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation. J Ocul Pharmacol Ther 27:173–178. doi:10.1089/jop.2010.0135 Ruan KH, Cervantes V, So SP (2009) Engineering of a novel hybrid enzyme: an anti-inflammatory drug target with triple catalytic activities directly converting arachidonic acid into the inflammatory prostaglandin E2. Protein Eng Des Sel 22:733–740. doi:10.1093/protein/gzp058 Nichols J, Snyder RW (1998) Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol 9:40–44. doi:10.1097/00055735-199808000-00007 Rothova A (2007) Inflammatory cystoid macular edema. Curr Opin Ophthalmol 18:487–492. doi:10.1097/ICU.0b013e3282f03d2e Sivaprasad S, Bunce C, Wormald R (2005) Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 89:1420–1422. doi:10.1136/bjo.2005.073817 Sivaprasad S, Bunce C, Crosby-Nwaobi R (2012) Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Rev CD004239. doi: 10.1002/14651858.CD004239.pub3 Yilmaz T, Cordero-Coma M, Gallagher MJ (2012) Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye (Lond) 26:252–258. doi:10.1038/eye.2011.296 Kim SJ, Schoenberger SD, Thorne JE, Ehlers JP, Yeh S, Bakri SJ (2015) Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology. Ophthalmology 122:2159–2168. doi:10.1016/j.ophtha.2015.05.014 Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. doi:10.1371/journal.pmed.1000097 Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group, Cochrane Statistical Methods Group (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. doi:10.1136/bmj.d5928 Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R, Brozek J, Vist G, Rind D, Akl EA, Schünemann HJ (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66:719–725. doi:10.1016/j.jclinepi.2012.03.013 Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 353:i1777. doi:10.1136/bmj.i1777 White IR, Barrett JK, Jackson D, Higgins JP (2012) Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 3:111–125. doi:10.1002/jrsm.1045 Li D, Wang T, Shen S, Cheng S, Yu J, Zhang Y, Zhang C, Tang H (2015) Effects of fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis. PLoS One 10:e0145066. doi:10.1371/journal.pone.0145066 Trinquart L, Chatellier G, Ravaud P (2012) Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Med Res Methodol 12:150. doi:10.1186/1471-2288-12-150 Hovanesian JA, Sheppard JD, Trattler WB, Gayton JL, Malhotra RP, Schaaf DT, Ng E, Dunn SH (2015) Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: integrated results from 2 pivotal phase 3 studies. J Cataract Refract Surg 41:2060–2068. doi:10.1016/j.jcrs.2015.10.053 Modi SS, Lehmann RP, Walters TR, Fong R, Christie WC, Roel L, Nethery D, Sager D, Tsorbatzoglou A, Philipson B, Traverso CE, Reiser H (2014) Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg 40:203–211. doi:10.1016/j.jcrs.2013.07.042 Walters TR, Goldberg DF, Peace JH, Gow JA, Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group (2014) Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology 121:25–33. doi:10.1016/j.ophtha.2013.07.006 Numaga J (2011) Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients. J Ophthal Inflamm Infect 1:147–155. doi:10.1007/s12348-011-0036-8 Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR, Bromfenac Ophthalmic Solution (Bromday) Once Daily Study Group (2011) Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology 118:2120–2127. doi:10.1016/j.ophtha.2011.04.035 Donnenfeld ED, Nichamin LD, Hardten DR, Raizman MB, Trattler W, Rajpal RK, Alpern LM, Felix C, Bradford RR, Villanueva L, Hollander DA, Schiffman RM (2011) Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmol 151:420.e1–426.e1. doi:10.1016/j.ajo.2010.09.003 Maxwell WA, Reiser HJ, Stewart RH, Cavanagh HD, Walters TR, Sager DP, Meuse PA (2008) Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. J Ocul Pharmacol Ther 24:593–599. doi:10.1089/jop.2008.0023 Stewart RH, Grillone LR, Shiffman ML, Donnenfeld ED, Gow JA, Bromfenac Ophthalmic Solution 0.09% Study Group (2007) The systemic safety of bromfenac ophthalmic solution 0.09%. J Ocul Pharmacol Ther 23:601–612. doi:10.1089/jop.2007.0040 Lane SS, Modi SS, Lehmann RP, Holland EJ (2007) Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 33:53–58. doi:10.1016/j.jcrs.2006.08.043 Scuderi B, Driussi GB, Chizzolini M, Salvetat ML, Beltrame G (2003) Effectiveness and tolerance of piroxicam 0.5% and diclofenac sodium 0.1% in controlling inflammation after cataract surgery. Eur J Ophthalmol 13:536–540 Solomon KD, Cheetham JK, DeGryse R, Brint SF, Rosenthal A (2001) Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 108:331–337. doi:10.1016/S0161-6420(00)00543-1 Stewart R, Grosserode R, Cheetham JK, Rosenthal A (1999) Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther 21:723–732. doi:10.1016/S0149-2918(00)88323-X Heier J, Cheetham JK, Degryse R, Dirks MS, Caldwell DR, Silverstone DE, Rosenthal A (1999) Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol 127:253–259. doi:10.1016/S0002-9394(98)00413-9 Flach AJ, Dolan BJ, Donahue ME, Faktorovich EG, Gonzalez GA (1998) Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology 105:1775–1779. doi:10.1016/S0161-6420(98)99053-4 Koçak I, Yalvaç IS, Koçak A, Nurözler A, Unlü N, Kasim R, Duman S (1998) Comparison of the anti-inflammatory effects of diclofenac and flurbiprofen eye drops after cataract extraction. Acta Ophthalmol Scand 76:343–345. doi:10.1034/j.1600-0420.1998.760318.x Diestelhorst M, Schmidl B, Konen W, Mester U, Raj PS (1996) Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation. J Cataract Refract Surg 22(Suppl 1):788–793. doi:10.1016/S0886-3350(96)80163-5 Blaydes JE Jr, Kelley EP, Walt JG, DeGryse RE, Harper DG, Novack GD (1993) Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. J Cataract Refract Surg 19:481–487. doi:10.1016/S0886-3350(13)80611-6 Kraff MC, Martin RG, Neumann AC, Weinstein AJ (1994) Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. J Cataract Refract Surg 20:138–144. doi:10.1016/S0886-3350(13)80153-8 Sabiston D, Tessler H, Sumers K, Osterle C, Cheetham JK, Duzman E, DeGryse R (1987) Reduction of inflammation following cataract surgery by the nonsteroidal anti-inflammatory drug, flurbiprofen. Ophthal Surg 18:873–877 Dastidar SG, Ganguly K, Chaudhuri K, Chakrabarty AN (2000) The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. Int J Antimicrob Agents 14:249–251. doi:10.1016/S0924-8579(99)00159-4 Serhan CN, Chiang N (2002) Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. ScientificWorldJournal 2:169–204. doi:10.1100/tsw.2002.81 Zhang JY, Feng YF, Cai JQ (2013) Phacoemulsification versus manual small-incision cataract surgery for age-related cataract: meta-analysis of randomized controlled trials. Clin Exp Ophthalmol 41:379–386. doi:10.1111/j.1442-9071.2012.02868.x Wielders LH, Lambermont VA, Schouten JS, van den Biggelaar FJ, Worthy G, Simons RW, Winkens B, Nuijts RM (2015) Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis. Am J Ophthalmol 160:968.e33–981.e33. doi:10.1016/j.ajo.2015.07.032 van Endt JJ, Veraart HG, Kramer R, Janssen AG, Sunder Raj P (1997) A comparison of two ophthalmic steroid-antibiotic combinations after cataract surgery. Eur J Ophthalmol 7:144–148 Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M, Acular LS for Cystoid Macular Edema (ACME) Study Group (2008) A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol 146:554–560. doi:10.1016/j.ajo.2008.04.036